



COMPANY CONTACT:

Endologix, Inc.
Paul McCormick
President and CEO
(949) 595-7200
www.endologix.com

INVESTOR CONTACTS:

Lippert/Heilshorn & Associates, Inc.
Bruce Voss (bvoss@lhai.com)
Jody Cain (jcain@lhai.com)
(310) 691-7100
www.lhai.com

**ENDOLOGIX TO PRESENT AT STEPHENS INC.
FALL INVESTMENT CONFERENCE**

IRVINE, Calif. (November 7, 2007) – Endologix, Inc. (Nasdaq: ELGX), the developer and manufacturer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that Paul McCormick, president and chief executive officer, will make a presentation to the investment community at the Stephens Inc. Fall Investment Conference on Wednesday, November 14, 2007 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time) at the Palace Hotel in New York City.

Interested investors may gain access to a live audio webcast and slide presentation via the Internet by visiting the Company's Web site at www.endologix.com. Please go to the Interviews/Presentations page on the Investor Relations section of the Web site. The presentation will be available and archived on the Web site for 30 days.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

#